DAMGO is a selective μ-opioid receptor (μ-OPR) agonist used to distinguish between μ- and δ-opioid receptors, particularly around their first extracellular loops; it is employed in studies investigating the regulation of neuronal responses to CXCL12 and its role in neuroprotection against N-methyl-D-aspartate (NMDA)-induced neurotoxicity; DAMGO abolishes the neuroprotective effect of CXCL12, thereby serving as a tool to examine mechanisms underlying neuronal survival and central nervous system (CNS) development and function.